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SCREENING FOR CYSTIC FIBROSIS: THE IMPORTANCE OF USING 
THE CORRECT TOOLS 
Uzma Shah, Tariq Moatter  
Director of Pediatric Gastroenterology, Hepatology and Nutrition Department of Pathology and Microbiology, The Aga Khan 
University, Karachi 
Background: Cystic Fibrosis (CF) is a potentially lethal genetic disorder. The most frequent 
mutation worldwide in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene 
is designated as the Delta F508 mutation. This mutation was found in only 33% of Pakistani 
patients studied.  Since the common Pakistani mutations remain to be identified, appropriate 
screening tools are required to identify disease. Sweat chloride determinations remain the gold 
standard for diagnosing CF. This study was done to emphasize the importance of using the correct 
tests. Methods: The study was conducted at the Aga Khan University Hospital. The CFTR delta 
F508 mutation was tested on blood samples from patients suspected with CF. Sweat chloride 
analysis using pilocarpine iontopharesis was done with a positive value of greater than 60 meq/L. 
Results: 57 pediatric samples were screened for the delta F508 mutation and were positive in only 
10.6 % of all patients tested. 12/57 (21%) had a preliminary sweat test. 6/12 (50%) of these 
patients had an abnormal sweat test and 3/6 patients with an abnormal sweat chloride (50 %) had 
deltaF508 mutations - 2/6 (33%) were homozygotes and 1 was a compound heterozygote. Since 
79% did not have a sweat test, it was difficult to assess whether this subset of patients had cystic 
fibrosis with a CFTR mutation other than the delta F508 tested or no CF. Conclusion: Sweat 
chloride analysis is critical to distinguish CF from other causes of severe pulmonary and 
pancreatic insufficiencies and to define patients requiring further analysis.  
Key words: Cystic fibrosis, sweat chloride, mutation analysis 
INTRODUCTION 
Cystic Fibrosis is the most common autosomal 
recessive, potentially lethal genetic disorder, 
associated with pulmonary and pancreatic 
insufficiency. The abnormality lies in a mutation in 
the Cystic Fibrosis Transmembrane Conductance 
Regulator (CFTR) gene. More than 1340 mutations 
in this gene have been identified worldwide to date. 
The most frequent mutation identified is designated 
as the Delta F508 mutation. This mutation, which is 
present in 70-100 % of CF patients of Caucasian 
origin, was found in only 33% of the Pakistani 
patients that we have studied so far (1). The CF 
mutations in the remaining 66 % of Pakistani patients 
have yet to be defined. 
Screening tools, such as sweat chloride 
analysis, are critical for the identification of those 
patients that would require further mutation analysis. 
Since the common Pakistani mutations still remain to 
be identified, sweat chloride determinations are 
extremely important to make a diagnosis of Cystic 
fibrosis. This study was done to emphasize the 
importance of using the correct screening tools to 
establish an unambiguous diagnosis of the disease. 
MATERIAL AND METHODS  
The study was conducted at the Aga Khan University 
Hospital, Karachi, Pakistan over the years 2002-
2003. This is a tertiary care facility that caters to 
patients from all over Karachi as well as from other 
areas of Pakistan.  
Patients with clinical suspicion for CF were 
identified. The mutation analysis for CFTR delta 
F508 was done on blood samples from all these 
patients using the amplification refractory mutation 
system and polymerase chain reactions. The delta 
F508 test was used as the sole means of diagnosis of 
CF for a period of time during which the sweat test 
was unavailable due to malfunction of the machine. 
The sweat chloride analysis as a screening tool was 
therefore used in only some of these patients. The 
sweat test used pilocarpine iontophoresis and a 
positive value was defined as a sweat chloride of 
greater than 60 meq/L. Meconium ileus was also 
considered as a positive outcome variable of CF and 
these patients were included in the study. We 
reviewed the charts of all patients hence screened for 
CF. 
RESULTS  
The Molecular Biology department at the Aga Khan 
University received 57 pediatric samples to be 
screened for the delta F508 mutation. 61.4% of the 
patients tested were suspected to have CF due to 
respiratory symptoms, 19.3% for malabsorption and 
diarrhea and 8.8 % for problems with failure to 
thrive. 3 patients had meconium ileus as a presenting 
feature (Table 1).  Of all these patients, however, 
only 12/57 (21%) patients had a preliminary sweat 
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chloride analysis. 6/12 (50%) of those tested with the 
sweat chloride analysis had an abnormal sweat 
chloride value (71-168, mean 109 meq/L) and  3 of 
these 6 patients (50 %) with an abnormal sweat 
chloride had delta F508 mutations -  2/6 (33%) were 
homozygotes and 1 was a compound heterozygote 
(the other mutation is still unknown).  Two of the 
three patients (66.7%) with meconium ileus had a 
homozygous delta F508 mutation. (Table 2) Overall, 
the mutation analysis for delta F508 was positive in 
only 10.6 % of all the patients tested. Importantly 
since 79% did not have an initial sweat chloride 
analysis, it would be difficult to assess whether this 
subset of patients had cystic fibrosis with a CFTR 
mutation other than the delta F508 or no cystic 
fibrosis at all. Two of the 57 patients (3.5%) did not 
have a screening sweat test but were heterozygous for 
delta F508. The sensitivity of the delta F508 test to 
diagnose CF when used alone is 43% with a 
specificity of a 100%. 
When combined with an initial sweat 
chloride, the delta F508 mutation analysis was 
positive in 50% of those with an abnormal sweat test 
result. We suspect that the remaining 50% may have 
a CFTR mutation other than the delta F508 tested. 
Table 1: Presenting features of patients tested for 
Cystic fibrosis 
Clinical features Percentage of 
patients (n) 
Respiratory symptoms 61.4% (35) 
Malabsorption and diarrhea 19.3% (11) 
Failure to thrive 8.8% (5) 
Liver disease, pancreatic 
disease and meconium ileus 
10.5% (6) 
Table 2: Results of sweat chloride and mutation 
analysis 
Miscellaneous features Number of 
patients 
Patients tested for delta F508 57 
Sweat test done 12/57 (21%) 
Elevated sweat Chloride 6/12 (50%) 
Elevated sweat Chloride with 
delta F508 allele 
3/6 (50%) 
Delta F508 with positive sweat 
chloride 
2/6(33%) 
Delta F508 in those with no 
preliminary sweat test 
2/45 (4.4%) 
Patients with meconium ileus 
homozygous for delta F508 
2/3 66.7% 
DISCUSSION  
Cystic fibrosis is a disease with varied clinical 
manifestations. Quinton and Knowles et al 2 had first 
suggested that the primary defect of cystic fibrosis 
may be in chloride transport. The clinical features of 
CF stem from the resultant mucous plugging in 
various organ systems. Allan et al.3 demonstrated that 
meconium ileus was also a feature of cystic fibrosis. 
An extension of this is the distal intestinal obstruction 
syndrome or DIOS known as a 'meconium ileus 
equivalent' that occurs in adolescents and adults with 
CF. This obstruction is the consequence of 
abnormally viscid mucofeaculant material in the 
terminal ileum and colon of these patients.  
Pancreatic Insufficiency is an important 
feature of cystic fibrosis. However, approximately 
15% of CF patients do not have pancreatic 
insufficiency, i.e., they are ‘pancreatic sufficient’. 
Kerem et al.4 have showed that phenotype/genotype 
correlations dictate whether pancreatic insufficiency 
or sufficiency is associated with different mutations 
at the CF locus.  
Mucus plugging in the lungs leads to areas 
of atelectasis and superimposed infections. Patients 
with cystic fibrosis therefore have an increased 
predisposition to the development of pulmonary 
disease. The organisms most frequently cultured from 
tracheal aspirates from patients with CF include 
Pseudomonas and Staphylococcus. Pier et al.5 found 
that cultured human airway epithelial cells expressing 
the delta-F508 allele of the CFTR gene demonstrate 
defective clearance of Pseudomonas that possibly 
leads to enhanced pulmonary infection with this 
organism in CF.  
Focal and mutlilobular biliary cirrhosis are 
considered path gnomonic of liver disease in CF6. 
The prevalence rates and the risk factors for the 
development of CF liver disease have varied 
considerably. 7  It is suggested that gene modifiers 
may influence disease expression and Gabolde et al 
have 8 demonstrated that the presence of cirrhosis in 
patients with cystic fibrosis may be associated with 
either homozygous or compound heterozygous 
mutant mannose-binding lectins.  
Congenital bilateral absence of the vas 
deferens as a cause of male infertility has also been 
described in cystic fibrosis.  
SCREENING  
Several guidelines have been prepared worldwide 
concerning screening for the cystic fibrosis gene 9. 
Screening tools considered have included the 
immune reactive trypsin test and the sweat chloride 
analysis.  
Newborn babies with CF have abnormally high levels 
of immunoreactive trypsin (IRT) in serum, which has 
been the basis for its use as a screening tool. The  
IRT test has a 90% detection rate for CF and a 0.3% 
false positive rate.  
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Other tests that have been used for screening for 
cystic fibrosis include measurement of nasal potential 
difference and conductance through mucosal biopsies 
when placed in Ussing chambers.  
The only screening tool currently available 
in Pakistan is the sweat chloride analysis. The 
Pilocarpine Sweat Test remains the gold standard for 
diagnosis. This test measures the concentration of 
chloride in the sweat. In the majority of CF patients 
with typical features and identified mutations the 
sweat test is diagnostic. A positive sweat test is then 
followed by a mutation analysis for the predominant 
mutations in the population.  
The indications for sweat testing include 
clinical features suggestive of CF, a family history of 
CF, a positive newborn screening test (such as IRT) 
and the suspicion of an atypical phenotype. A 
positive result is described as a sweat chloride of 
greater than 60 mmol/L, equivocal values are those 
between 40-60 mmol/L and a negative test is 
described as values less than 40 mmol/L. A value of 
40-60 mmol/L in infancy is however considered 
suspect for CF 9,10. Borderline sweat results are seen 
with some mutations such as in R117H, R334W, and 
P67L 11,12. Patients with the F508/S1235R may have 
negative sweat tests. 
The sweat test can be done in term infants 
older than 7 days of age but preferably should be 
done in infants after 2 weeks of age and when they 
are greater than 3 kg in weight13,14. In a recent 
population based study in infants, of the 98 CF-
screened-positive affected infants for whom sweat 
results had been reported, 84/98 (86%) had values 
that were clearly positive and 13 of the remaining 14 
had sweat-test results that are consistent with 
expectations for a particular CF genotype 15.   
The diagnosis of CF can however remain 
uncertain in patients with clinical features of CF but 
intermediate sweat chloride values and the absence of 
identified mutations. It is also important to note that 
the sweat chloride concentration does not correlate 
with disease severity and a lower concentration does 
not necessarily predict a milder pulmonary course in 
patients with cystic fibrosis 16,17.   
A positive sweat chloride value is an 
important tool to distinguish CF from other causes of 
severe pulmonary and pancreatic insufficiencies. It 
also serves to define those patients who require 
further mutation analysis. In the New England 
Newborn Screening program, 50% of the patients 
were identified by Delta F508 testing alone while 
75% were identified when the mutation analysis was 
expanded to include several genetic mutations18. 
Since, 79% of our patients tested for delta F508, with 
symptoms suggestive of CF, did not have a 
preliminary sweat test it was very difficult to assess 
whether this subset of patients had CF with a CFTR 
mutation other than delta F508 or they had a disease 
other than cystic fibrosis. When combined with an 
initial sweat chloride, the delta F508 mutation 
analysis was positive in 50% of those with an 
abnormal sweat test result. We suspect that the 
remaining 50% may have a CFTR mutation other 
than the delta F508 tested. We are now in the process 
of studying the common mutations in CF in our 
population. 
Only a small fraction 3.5% of the 57 patients 
in this study had a positive mutation analysis in the 
absence of a preliminary screening sweat chloride.  
SUMMARY  
Since delta F508 is not present in 100% of Pakistani 
CF patients, making the diagnosis of CF on the basis 
of the presence of one mutation alone would 
therefore lead to many false negative diagnoses. We 
are in the process of identifying the common 
mutations in our population that will help in the 
establishment of a diagnosis of CF. In the absence of 
other screening tests in Pakistan, sweat chloride 
analysis therefore serves as an integral screening tool 
for CF. 
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